We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cerner, Duke Clinical Research Launch Risk Calculator App
Read MoreHide Full Article
In a bid to integrate healthcare data across multiple EHR suppliers and check cardiac risk, Cerner Corporation recently launched an atherosclerotic cardiovascular disease (ASCVD) Risk Calculator app in collaboration with Duke Clinical Research Institute.
Is ASCVD Risky?
ASCVD is a severe case of Coronary artery disease that causes heart attack, cardiac arrest and fatal or non-fatal stroke.
Considering the risks, American College of Cardiology and American Heart Association prescribed a 10-year calculator to identify adults who need statin therapy. For investors’ notice Statins are a particular class of lipid-lowering medications, which reduce cardiovascular disease.
Per management, the latest development comes in the right time as Cerner’s Risk Calculator app also helps health care providers estimate 10-year and lifetime ASCVD risk for patients based on age, race, sex, blood pressure, cholesterol levels, smoking status and diabetes status.
A New Addition to Cerner’s EHR Profile
Cerner and Duke Clinical Research Institute used Cerner Open Developer Experience (code) to develop the software. Through this open source code, doctors from Duke Clinical Research Institute provided clinical direction to create an app that can be embedded within Cerner’s electronic health record (EHR) for each patient.
The latest trend of EHR, or electronic health record, in the U.S. MedTech space has been gaining prominence. Cerner has been dominating the headlines in this respect, courtesy of efforts to digitize its EHR systems.
Apart from this, Cerner's HealtheIntent is a big data platform, which provides the company with significant exposure to AI trends in the medical world. HealtheIntent can fetch data from any EHR system, pharmacy benefits managers and insurance claims.
Share Price Lacks Luster
Cerner's shares have gained 6.9% in a month’s time against the industry's rally of 9.5%. However, the current level is higher than the S&P 500 index's gain of 0.3%. Regulatory headwinds and cutthroat competition acted as major dampeners.
However, we believe that developments like these will help the stock to perform better in the bourse in the coming days.
Penumbra has a long-term expected earnings growth rate of 20%, while the same for Integer Holdings and Patterson Companies is pinned at 15% and 8.3%, respectively.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Cerner, Duke Clinical Research Launch Risk Calculator App
In a bid to integrate healthcare data across multiple EHR suppliers and check cardiac risk, Cerner Corporation recently launched an atherosclerotic cardiovascular disease (ASCVD) Risk Calculator app in collaboration with Duke Clinical Research Institute.
Is ASCVD Risky?
ASCVD is a severe case of Coronary artery disease that causes heart attack, cardiac arrest and fatal or non-fatal stroke.
Considering the risks, American College of Cardiology and American Heart Association prescribed a 10-year calculator to identify adults who need statin therapy. For investors’ notice Statins are a particular class of lipid-lowering medications, which reduce cardiovascular disease.
Per management, the latest development comes in the right time as Cerner’s Risk Calculator app also helps health care providers estimate 10-year and lifetime ASCVD risk for patients based on age, race, sex, blood pressure, cholesterol levels, smoking status and diabetes status.
A New Addition to Cerner’s EHR Profile
Cerner and Duke Clinical Research Institute used Cerner Open Developer Experience (code) to develop the software. Through this open source code, doctors from Duke Clinical Research Institute provided clinical direction to create an app that can be embedded within Cerner’s electronic health record (EHR) for each patient.
The latest trend of EHR, or electronic health record, in the U.S. MedTech space has been gaining prominence. Cerner has been dominating the headlines in this respect, courtesy of efforts to digitize its EHR systems.
Apart from this, Cerner's HealtheIntent is a big data platform, which provides the company with significant exposure to AI trends in the medical world. HealtheIntent can fetch data from any EHR system, pharmacy benefits managers and insurance claims.
Share Price Lacks Luster
Cerner's shares have gained 6.9% in a month’s time against the industry's rally of 9.5%. However, the current level is higher than the S&P 500 index's gain of 0.3%. Regulatory headwinds and cutthroat competition acted as major dampeners.
However, we believe that developments like these will help the stock to perform better in the bourse in the coming days.
Cerner has a Zacks Rank #3 (Hold).
Want More from the MedTech Space?
A few better-ranked stocks in the MedTech space are Penumbra, Inc. (PEN - Free Report) , Integer Holdings Corp. (ITGR - Free Report) and Patterson Companies, Inc. (PDCO - Free Report) . Patterson Companies carries a Zacks Rank #2 (Buy). Integer and Penumbra sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Penumbra has a long-term expected earnings growth rate of 20%, while the same for Integer Holdings and Patterson Companies is pinned at 15% and 8.3%, respectively.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>